首页> 美国卫生研究院文献>BMC Womens Health >Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann’s Thrombasthenia: illustrated case series
【2h】

Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann’s Thrombasthenia: illustrated case series

机译:左炔诺孕酮释放子宫内系统治疗格兰仕曼型血小板减少症的青少年经期严重出血

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGlanzmann’s Thrombasthenia (GT) is an inherited genetic disorder caused by defects in the platelet membrane glycoproteins IIb/IIIA, and is associated with heavy menstrual bleeding (HMB). HMB is a common complication in female patients, and many adolescent girls with this disease have issues with HMB beginning at menarche. The available treatment modalities including anti-fibrinolytics, nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies though are effective, their associated side effects, limited efficacy and the poor compliance is a challenge in management of HMB. Levonorgestrel-releasing intrauterine system (LNG-IUS) has been a potential alternative to overcome this challenge. The use of the LNG-IUS for the management of HMB in adolescents with GT is explored in this case series.
机译:背景:格兰兹曼血小板减少症(GT)是由血小板膜糖蛋白IIb / IIIA缺陷引起的遗传性遗传疾病,与月经大量出血(HMB)有关。 HMB是女性患者的常见并发症,许多患有这种疾病的少女从初潮开始就患有HMB问题。可用的治疗方式包括抗纤维蛋白溶解药,非甾体类抗炎药(NSAIDs)和激素疗法虽然有效,但它们相关的副作用,疗效有限和依从性差是HMB管理中的一个挑战。左炔诺孕酮释放子宫内系统(LNG-IUS)已成为克服这一挑战的潜在选择。在本案例系列中,探讨了将LNG-IUS用于GT青春期HMB的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号